Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Arrowhead Pharmaceuticals, Inc., Tango Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Latest Biotechnology and Arrowhead Pharmaceuticals, Inc., Tango Therapeutics, Inc. Stock News

As of October 26, 2026, Arrowhead Pharmaceuticals, Inc. had a $8.3 billion market capitalization, compared to the Biotechnology median of $222.9 million. Arrowhead Pharmaceuticals, Inc.’s stock is down 9.9% in 2026, up 1.6% in the previous five trading days and up 57.91% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc. does not have a price-earnings ratio. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $669.5 million with a -47.8% net profit margin. Year-over-year quarterly sales growth most recently was 170.9%. Analysts expect adjusted earnings to reach $-3.513 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

As of October 26, 2026, Tango Therapeutics, Inc. had a $3.7 billion market cap, putting it in the 64th percentile of all stocks. Tango Therapeutics, Inc.’s stock is up 153.1% in 2026, down 11.2% in the previous five trading days and up 194.75% in the past year.

Currently, Tango Therapeutics, Inc. does not have a price-earnings ratio. Tango Therapeutics, Inc.’s trailing 12-month revenue is $53.8 million with a -229.9% net profit margin. As of October 26, 2026, Tango Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.395 per share for the current fiscal year. Tango Therapeutics, Inc. does not currently pay a dividend.

How We Compare Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Arrowhead Pharmaceuticals, Inc.	ARWR	F
Tango Therapeutics, Inc.	TNGX	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Arrowhead Pharmaceuticals, Inc. has a Growth Score of 14, which is Very Weak. Tango Therapeutics, Inc. has a Growth Score of 19, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Tango Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Tango Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Arrowhead Pharmaceuticals, Inc.	ARWR	B
Tango Therapeutics, Inc.	TNGX	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Arrowhead Pharmaceuticals, Inc. has a Momentum Score of 77, which is Strong. Tango Therapeutics, Inc. has a Momentum Score of 97, which is Very Strong.

The Momentum Grade Winner: Tango Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Tango Therapeutics, Inc. is considered to have stronger momentum compared to Arrowhead Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Tango Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Arrowhead Pharmaceuticals, Inc.	ARWR	D
Tango Therapeutics, Inc.	TNGX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Arrowhead Pharmaceuticals, Inc. has a Earnings Estimate Score of 40, which is Negative. Tango Therapeutics, Inc. has a Earnings Estimate Score of 31, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Tango Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Tango Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc. Grades

In addition to Growth, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Arrowhead Pharmaceuticals, Inc., Tango Therapeutics or Inc. Stock?

Overall, Arrowhead Pharmaceuticals, Inc. stock has a Growth Score of 14, Momentum Score of 77 and Estimate Revisions Score of 40.

Tango Therapeutics, Inc. stock has a Growth Score of 19, Momentum Score of 97 and Estimate Revisions Score of 31.

Comparing Arrowhead Pharmaceuticals, Inc., Tango Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.